Triomics Prism Trial Matching

Triomics builds AI agents that read notes, reports and faxes in a patient record and return structured, cited answers for cancer centers and life sciences teams. The company lists its address at One World Trade Center, New York, and does not state a founding year on its website.

Its Prism product screens every patient with an upcoming appointment against all active trials in a site's portfolio, refreshing nightly into an EHR in-basket or worklist. It is powered by the OncoLLM reasoning model, integrates natively with Epic and OncoEMR, and is used by NCI-designated cancer centers.

• Patient-to-trial matching: matches reach the EHR in-basket or worklist before clinic.
• Trial-to-patient matching: finds the eligible cohort for new studies and feasibility checks.
• Continuous tracking: re-evaluates patients when biomarkers or therapy lines change.
• Cited evidence: each match links to pathology, molecular and note-level sources.
• EHR integration: native Epic and OncoEMR support, listed on the Epic App Marketplace.
• OncoLLM: oncology reasoning model behind the platform.

Large oncology hospitals in Vietnam could screen records for global trials once EHR data is structured. CROs could use trial-to-patient mode for feasibility checks before selecting sites.

Screens patients against every active trial without a study-specific build. Gives coordinators a prioritized, cited worklist before clinic. Re-evaluates patients as charts update. Supports audit by research offices and IRBs. Vendor-stated figures include 30% higher accruals and 70% faster screening.

Cancer centers face large screening workloads, and LLM-based chart review is being adopted to find eligible patients. Vietnamese oncology hospitals that join international studies face the same manual screening burden as electronic records spread.

Partners named on the site include Memorial Sloan Kettering, Yale Cancer Center, Mount Sinai and Regenstrief/IU Health. 2025-10: MSK announced deployment. 2026-01: Mount Sinai launch.